Our top pick for
Beginners

Addex Therapeutics Ltd is a biotechnology business based in the US. Addex Therapeutics shares (ADXN) are listed on the NASDAQ and all prices are listed in US Dollars. Addex Therapeutics employs 26 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
Latest market close | $1.05 |
---|---|
52-week range | $1.05 - $10.90 |
50-day moving average | $3.83 |
200-day moving average | $6.02 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-3.26 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.05 from 2022-06-28
1 week (2022-06-22) | -5.15% |
---|---|
1 month (2022-05-27) | -71.47% |
3 months (2022-03-29) | -78.06% |
6 months (2021-12-29) | -83.62% |
1 year (2021-06-29) | -89.59% |
---|---|
2 years (2020-06-29) | -88.33% |
3 years (2019-06-25) | N/A |
5 years (2017-06-25) | N/A |
Revenue TTM | $2.5 million |
---|---|
Gross profit TTM | $-9,687,235 |
Return on assets TTM | -50.84% |
Return on equity TTM | -110.16% |
Profit margin | 0% |
Book value | $2.05 |
Market capitalisation | $7.4 million |
TTM: trailing 12 months
We're not expecting Addex Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Addex Therapeutics's shares have ranged in value from as little as $1.05 up to $10.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Addex Therapeutics's is 1.3249. This would suggest that Addex Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. ; Indivior PLC; and The Charcot"Marie"Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Everything we know about the NYIAX IPO, plus information on how to buy in.
Everything we know about the Adamas One Corp IPO, plus information on how to buy in.
Everything we know about the Glucose Health IPO, plus information on how to buy in.
Everything we know about the Boustead Wavefront IPO, plus information on how to buy in.
Everything we know about the ParaZero Technologies IPO, plus information on how to buy in.